
Merck & Co Inc on Tuesday reported a 54.7per cent rise in third-quarter profit, helped by strong sales of blockbuster cancer drug Keytruda and rebound in sales of its key drugs.
Merck & Co Inc on Tuesday reported a 54.7per cent rise in third-quarter profit, helped by strong sales of blockbuster cancer drug Keytruda and rebound in sales of its key drugs.